Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) traded up 15.3% during trading on Monday . The company traded as high as $1.68 and last traded at $1.58. 866,786 shares were traded during trading, an increase of 82% from the average session volume of 477,068 shares. The stock had previously closed at $1.37.
Tiziana Life Sciences Trading Down 3.6%
The stock has a 50-day moving average price of $1.22 and a 200 day moving average price of $1.03.
Institutional Investors Weigh In On Tiziana Life Sciences
A number of hedge funds and other institutional investors have recently bought and sold shares of TLSA. Cubist Systematic Strategies LLC acquired a new stake in Tiziana Life Sciences in the 1st quarter valued at approximately $25,000. Bison Wealth LLC acquired a new stake in Tiziana Life Sciences in the 4th quarter valued at approximately $30,000. OMERS ADMINISTRATION Corp acquired a new stake in Tiziana Life Sciences in the 1st quarter valued at approximately $156,000. Geode Capital Management LLC raised its position in Tiziana Life Sciences by 12.4% in the 4th quarter. Geode Capital Management LLC now owns 245,722 shares of the company's stock valued at $171,000 after buying an additional 27,041 shares during the last quarter. Finally, Jane Street Group LLC raised its position in Tiziana Life Sciences by 968.2% in the 1st quarter. Jane Street Group LLC now owns 167,542 shares of the company's stock valued at $181,000 after buying an additional 151,858 shares during the last quarter.
About Tiziana Life Sciences
(
Get Free Report)
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
Further Reading
Before you consider Tiziana Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.
While Tiziana Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
